Fosun Pharma (02196.HK): The registration application for the listing of fumaric acid fesoterodine capsules has been approved by the National Medical Products Administration.

Financial news from Zhitong, Fosun Pharma (02196.HK) announced that its holding subsidiary, Jinzhou Aohong Pharmaceutical Co., Ltd., recently received approval from the National Medical Products Administration (NMPA) for the marketing registration application of the citrate voviscic lysine capsule (trade name: Futining, project code: FCN-437c; hereinafter referred to as "the new drug"). This approval is indicated for combination with fluvisquine in hormone receptor (HR) positive, human epidermal growth factor 2 (HER2) negative recurrent or metastatic adult breast cancer patients who have experienced disease progression after previous endocrine therapy.